Cross Road Biotech

www.crossroadbiotech.com

CRB bio II Fund Launched to Invest in Early Stage Biotech in Spain. The Fund will be managed by a new VC Firm CRB Inverbío a Spanish company with wide experience and track record in bio investments. Now raising with an expected final closing at 60M euros. Please contact [email protected] for more details CRB is a Spanish Private Equity company founded in 2004 that invests in innovative, high potential biotech start ups in early phases. CRB´s mission is to fill the gap between science and industry and is engaged in the task of transforming bio-medic research projects into profitable businesses. CRB has clear competitive advantages: •Experienced, multifunctional management team •Access to the scientific sources and inter-communication capability with the scientific teams •Willingness to invest in early development phases •When feasible, taking a controlling equity position in the company •Specialization •Hands on involvement in the portfolio companies: •Ability to raise non-diluting public financing •Few “off limits” and investment restrictions CRB has a diversified portfolio in relevant therapeutic and diagnostic areas of global impact like Cancer, Alzheimer, Liver diseases, VIH etc…. CRB also wants to increase the visibility of the projects in the current portfolio and explore new alliances and collaborations. CRB projects have global relevance hence wants to develop long range relationships with stakeholders in the pharma/biotech industry

Read more

Reach decision makers at Cross Road Biotech

Lusha Magic

Free credit every month!

CRB bio II Fund Launched to Invest in Early Stage Biotech in Spain. The Fund will be managed by a new VC Firm CRB Inverbío a Spanish company with wide experience and track record in bio investments. Now raising with an expected final closing at 60M euros. Please contact [email protected] for more details CRB is a Spanish Private Equity company founded in 2004 that invests in innovative, high potential biotech start ups in early phases. CRB´s mission is to fill the gap between science and industry and is engaged in the task of transforming bio-medic research projects into profitable businesses. CRB has clear competitive advantages: •Experienced, multifunctional management team •Access to the scientific sources and inter-communication capability with the scientific teams •Willingness to invest in early development phases •When feasible, taking a controlling equity position in the company •Specialization •Hands on involvement in the portfolio companies: •Ability to raise non-diluting public financing •Few “off limits” and investment restrictions CRB has a diversified portfolio in relevant therapeutic and diagnostic areas of global impact like Cancer, Alzheimer, Liver diseases, VIH etc…. CRB also wants to increase the visibility of the projects in the current portfolio and explore new alliances and collaborations. CRB projects have global relevance hence wants to develop long range relationships with stakeholders in the pharma/biotech industry

Read more
icon

Country

icon

City (Headquarters)

Madrid

icon

Employees

11-50

icon

Founded

2002

icon

Estimated Revenue

$1,000,000 to $5,000,000

icon

Social

  • icon

Employees statistics

View all employees

Potential Decision Makers

  • Partner and Director

    Email ****** @****.com
    Phone (***) ****-****
  • Chairperson

    Email ****** @****.com
    Phone (***) ****-****

Technologies

(5)

Reach decision makers at Cross Road Biotech

Free credits every month!

My account

Sign up now to uncover all the contact details